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Interim guidlines for the evaluation and testing of infants whose mothers 
traveled to or resided in an area with ongoing Zika virus transmission* 
during pregnancy† §
Infant whose mother traveled to or resided in an area 
with Zika virus transmission during pregnancy
Microcephaly or intracranial calcifications 
detected prenatally or at birth
Conduct thorough physical examination 
and perform Zika virus testing in infant
Positive or inconclusive 
test for Zika virus 
infection in infant
Perform additional clinical 
evaluation, report case, 
and assess for possible 
long-term sequelae 
Negative tests for Zika 
virus infection in infant 
Evaluate and treat for 
other possible etiologies
No microcephaly or intracranial 
calcifications detected prenatally or at birth
Positive or inconclusive test for 
Zika virus infection in mother
Conduct thorough physical 
examination and perform Zika 
virus testing in infant
Positive or inconclusive 
test for Zika virus 
infection in infant
Perform additional clinical 
evaluation, report case, 
and assess for possible 
long-term sequelae
Negative tests for Zika 
virus infection in infant
Routine care of infant, 
including appropriate 
follow-up on any clinical 
findings
Negative or no Zika virus testing 
performed on mother
Routine care of infant, 
including appropriate follow-
up on any clinical findings
*Areas with Zika virus transmission are listed on CDC’s website at http://wwwnc.cdc.gov/travel/notices.
†Microcephaly defined as occipitofrontal circumference less than the third percentile for gestational age and sex based on standard growth curves, not explained by other etiologies.
§Laboraory evidence of Zika virus infection includes 1) detectable Zika virus, Zika virus RNA, or Zika virus antigen in any clinical specimen; or 2) positive Zika virus Immunoglobulin 
M (IgM) with confirmatory neutralizing antibody titers that are >4-fold higher than dengue virus neutralizing antibody titers in serum or cerebrospinal fluid. Testing is considered 
inconclusive if Zika virus neutralizing antibody titers are <4-fold higher than dengue virus neutralizing antibody titers.
More information on laboratory testing for Zika virus infection is available at http://www.cdc.gov/zika/state-labs/index.html.
Updated Interim Guidelines and other resources for healthcare providers available at  
http://www.cdc.gov/zika/hc-providers/index.html
www.cdc.gov/zika
